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Targeted next generation 
sequencing in Italian patients 
with Usher syndrome: phenotype-
genotype correlations
Chiara M. Eandi1, Laura Dallorto1, Roberta Spinetta1, Maria Pia Micieli2, Mario Vanzetti3, 
Alessandro Mariottini4, Ilaria Passerini4, Francesca Torricelli4, Camilla Alovisi1 &  
Cristiana Marchese3
We report results of DNA analysis with next generation sequencing (NGS) of 21 consecutive Italian 
patients from 17 unrelated families with clinical diagnosis of Usher syndrome (4 USH1 and 17 USH2) 
searching for mutations in 11 genes: MYO7A, CDH23, PCDH15, USH1C, USH1G, USH2A, ADGVR1, 
DFNB31, CLRN1, PDZD7, HARS. Likely causative mutations were found in all patients: 25 pathogenic 
variants, 18 previously reported and 7 novel, were identified in three genes (USH2A, MYO7A, ADGRV1). 
All USH1 presented biallelic MYO7A mutations, one USH2 exhibited ADGRV1 mutations, whereas 16 
USH2 displayed USH2A mutations. USH1 patients experienced hearing problems very early in life, 
followed by visual impairment at 1, 4 and 6 years. Visual symptoms were noticed at age 20 in a patient 
with homozygous novel MYO7A missense mutation c.849G > A. USH2 patients’ auditory symptoms, 
instead, arose between 11 months and 14 years, while visual impairment occurred later on. A 
homozygous c.5933_5940del;5950_5960dup in USH2A was detected in one patient with early deafness. 
One patient with homozygous deletion from exon 23 to 32 in USH2A suffered early visual symptoms. 
Therefore, the type of mutation in USH2A and MYO7A genes seems to affect the age at which both 
auditory and visual impairment occur in patients with USH.
Usher Syndrome (USH) is a syndromic inherited retinal dystrophy (IRD). It is a clinically and genetically heter-
ogeneous autosomal recessive disorder, characterized by retinitis pigmentosa (RP)1–3 and bilateral sensorineural 
deafness, with or without vestibular dysfunction.
USH has a prevalence of 3.2 to 6.2 cases per 100000, thus representing the leading genetic cause of combined 
hearing and vision loss4,5. Three different clinical subtypes have been so far identified based on hearing, vestibular 
and visual symptoms6. Type 1 (USH1) is the most severe form of USH, characterized by severe congenital deaf-
ness, vestibular dysfunction and prepubertal RP onset7. Deafness is less severe in USH type 2 (USH2), for which 
the vestibular function remains normal, while RP symptoms generally occur during puberty7. Finally, USH type 3 
(USH3) is characterized by post lingual hearing loss, while the age of RP occurrence is offset between the second 
to fourth decade and can be subject to variable vestibular dysfunctions6. Sixteen loci and thirteen disease-causing 
genes associated with USH have been so far identified (https://sph.uth.edu/retnet/), thus demonstrating the wide 
genetic heterogeneity of this syndrome. Such heterogeneity makes molecular diagnosis with Sanger sequencing 
of single genes rather challenging, since this particular diagnostic strategy, although accurate, requires a lot of 
time and resources6. Microarray technology for the simultaneous detection of known mutations in Usher related 
genes, instead, has proven to perform poorly, proving diagnostic efficiency as low as 12%, when applied on the 
Italian population8. Nevertheless, thanks to the recent availability of next generation sequencing (NGS) in rou-
tine genetic testing, it is now possible to simultaneously screen an increasing number of selected genes (targeted 
NGS), as well as the whole exome or the entire genome. So far, NGS has proven to be a rapid and cost-effective 
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diagnostic method, which is also a useful tool for the identification of novel disease-causing genes9. Targeted NGS 
is being currently applied on patients affected by hereditary diseases with high gene heterogeneity, such as Usher 
syndrome and, both syndromic and non-syndromic, inherited retinal dystrophies10–13.
Deeper understanding of the genetic basis allows further analysis of possible genotype-phenotype correla-
tions. Besides being useful for genetic counselling, such knowledge base is fundamental to an accurate clinical 
diagnosis and prognosis of individual patients and thus represents an invaluable tool for the development of 
personalized treatments.
The report describes the phenotypes associated with the mutations detected during genetic testing with tar-
geted NGS. The tests were carried out on a group of 21 consecutive Italian patients from 17 unrelated families 
affected by Usher syndrome who were seeking genetic counselling.
Methods
Patients. This is a retrospective study. The study comprises 21 consecutive Italian patients (15 males and 6 
females) from 17 unrelated families with a clinical diagnosis of Usher syndrome who were seeking genetic coun-
selling at the Mauriziano Hospital in Torino, Italy. The pedigrees of the 17 families are reported in Fig. 1.
The data collection complies with the Italian law. The study was conducted in accordance with the provisions 
stated in the Declaration of Helsinki (59th World Medical Association General Assembly; Seoul, Korea; October 
2008).
All the patients and their relatives were duly informed about the advantages and limitations of the test and 
were required to sign informed consent. Detailed medical, personal and family history was obtained from the 
patients and their relatives, specifically recording the age of onset of deafness, visual deficiency and equilibrium 
impairment.
In most cases, the available ophthalmological clinical data were composed by slit-lamp anterior segment and 
fundus examinations, best corrected visual acuity, Goldmann applanation tonometry, electroretinogram (ERG), 
visual evoked potentials (VEP), visual field test, optic coherence tomography (OCT). A few patients had also 
sustained colour vision tests, fundus autofluorescence and fluorescein angiography.
DNA analysis. Within the framework of the Italian rare diseases registry, the diagnostic genetic unit of AOU 
Careggi in Firenze offers National Health System patients free genetic testing for IRD. Genetic testing is mainly 
requested to confirm clinical diagnosis, for genetic counselling for patients and their families and to allow partic-
ipation in gene therapy trials.
Genomic DNA was isolated from peripheral leukocytes, using the QiaSymphony DNA Blood Midi kit on the 
QIAsymphony SP workstation (Qiagen), according to the manufacturer’s protocol.
A custom Haloplex panel was designed using Agilent’s online SureDesign tool (https://earray.chem.agilent.
com/suredesign/index.htm), Targeted NGS of coding regions and exon-intron junctions of a panel of 11 genes 
were performed: MYO7A (MIM 276903), CDH23 (MIM 605516), PCDH15 (MIM 605514), USH1C (MIM 
605242), USH1G (MIM 607696), USH2A (MIM 608400), ADGVR1 (MIM 602851), DFNB31 (MIM 607928), 
CLRN1 (MIM 606397), PDZD7 (MIM 612971), HARS (MIM 142810). Genes ABDH12 (MIM 613599,612674), 
CEP250 (MIM 609689) and CIB2 (MIM 614869) were not included in the panel because mutations in these 
genes have only been recorded in a few non-Caucasian families. PDZD7 gene was included because it has been 
suggested to be a modifier gene in subjects with USH2A mutations and potentially involved with ADGRV1 in 
digenic USH214.
The target regions were captured using the Agilent HaloPlex Target Enrichment System Kits for Illumina 
Sequencing following Agilent protocols. The captured target libraries were amplified by PCR, quality controlled 
and quantified using the BioAnalyzer 2100 (Agilent Technologies, Inc. Santa Clare, CA). Equimolar amounts of 
differentially indexed samples were pooled before pair-ended sequencing at 300 cycles on the Illumina MiSeq 
platform (Illumina Inc., San Diego, CA, USA). In addition, the deep intronic variant (c.7595-2144A > G) in 
intron 40 of USH2A gene was searched15.
The criteria used to distinguish new mutations from polymorphisms is ExAC frequency. We filtered variants 
with a MAF < 0.05. All the new mutations reported in this study are not validated at RNA and protein levels.
The new mutations reported were investigated in 48 healthy subjects (20 females, 28 males) with Sanger 
sequencing.
For the new point mutations leading to aminoacid substitution, pathogenicity predictions from Bioinformatic 
tools SIFT, PhyloP, AGVGD, MutationTaster and Polyphen2 were compared.
For intronic mutations, although our laboratory cannot validate that the mutations observed indeed affect the 
splicing process, the bioinformatics tools available predicted all of them to be pathogenic; furthermore the vari-
ants were at the exon-intron junction and such variants both at RNA level and in classical genetics are reported 
to affect the splicing process.
The presence of all pathogenic and likely pathogenic variants detected was confirmed with Sanger sequenc-
ing, processed with the automated Core System (Beckman Coulter, Fullerton, CA). After purification, ampli-
cons were sequenced on the 3730 DNA Analyzer (ABI, Foster City, CA). The sequences were assembled and 
analyzed using SeqScape software (ABI). Variants of unknown pathogenicity were interpreted with Alamut 2.6 
(Interactive Biosoftware, Rouen, France), a decision-support software application for medical molecular genetics. 
The software relies on web-based prediction software, such as Align-GVGD, SIFT, PolyPhen, Mutation Taster 
(hosted by Interactive Biosoftware). Note that Alamut 2.6 scoring systems provide a predictive evaluation only for 
missense variants. In selected patients multiplex ligation-dependent probe amplification (MLPA) was also per-
formed. The MLPA reaction (P361-A1/P362-A2 SALSA MLPA kit; MRC Holland, Amsterdam, The Netherlands) 
was performed according to the manufacturer’s recommendations. One microliter of each reaction product was 
www.nature.com/scientificreports/
3Scientific REPoRTS | 7: 15681  | DOI:10.1038/s41598-017-16014-z
separated on a POP-7 polymer with capillary electrophoresis using the 3730 DNA Analyzer (ABI). Freely availa-
ble software provided by MRC Holland was used to analyze the MLPA data (Coffalyser; MRC Holland).
When relatives were available (14 families), segregation analysis was performed.
Results
DNA analysis. DNA analysis results were in accordance with the diagnosis for all patients clinically diag-
nosed with USH. The average of sequencing depth was about >99.9%. We obtained about 70 variants for each 
sample. We filtered for function and frequency according to ACMG guidelines16. We obtained about 1–3 variants 
for sample that were validated by Sanger sequencing.
Figure 1. Pedigrees of the families included in the study.
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Likely causative mutations were identified in three Usher related genes: USH2A, MYO7A, ADGRV1. For the 
causative mutations found in this study, reported and novel, there aren’t neither in vivo functional experiments 
showing that the mutations cause the USH phenotype, nor in vitro experiments showing that the mutations will 
cause genetic dysfunction.
The results are reported in Table 1. Further heterozygous mutations in Usher related genes were observed in 
nine patients (Table 2). In Table 3 the frequency in our normal population of the new mutation and the patho-
genecity prediction from Bioinformatic tools SIFT, PhyloP, AGVGD, MutationTaster and Poluphen2 for the new 
point mutations leading to aminoacid substitution, are reported. In Fig. 1 the pedigree of the 17 families and the 
genotypes of the patients and of their relatives are reported.
Phenotype. Details of the phenotypes are reported in Table 4.
Discussion
This report retrospectively analyses the clinical and genetic data of 21 consecutive Italian patients from 17 unre-
lated families affected by Usher syndrome undergoing genetic analysis by targeted NGS of 11 genes (MYO7A, 
CDH23, PCDH15, USH1C, USH1G, USH2A, ADGVR1, DFNB31, CLRN1, PDZD7, HARS). USH2 syndrome was 
Family Patient Age* Sex
Onset 
HL (yrs)
Onset VI 
(yrs) Gene Mutation Protein Reported Segregation
1 TO1 47 F 14 20 USH2A c.2299del (p.Glu767Serfs*21) Heterozygous Reported YES
USH2A c.4732C > T (p.Arg1578Cys) Heterozygous Reported
2 TO2 35 M 7 16 USH2A c.2299del (p.Glu767Serfs*21) Heterozygous Reported YES
USH2A c.5603T > G (p.Phe1868Cys) Heterozygous Reported
2 TO3 29 M 6 16 USH2A c.2299del (p.Glu767Serfs*21) Heterozygous Reported YES
USH2A c.5603T > G (p.Phe1868Cys) Heterozygous Reported
3 TO4 17 M 3 10 USH2A c.2299del (p.Glu767Serfs*21) Heterozygous Reported YES
USH2A c.563A > G (p.Tyr188Cys) Heterozygous Novel
4 TO5 58 M 7 12 USH2A c.2168-1G > C p? Heterozygous Reported Not done
USH2A c.9815C > T (p.Pro3272Leu) Heterozygous Reported
5 TO6 32 M Cong 6 MYO7A c.4065del (p.His1355Glnfs*44) Heterozygous Reported YES
MYO7A c.5886_5888del (p.1963del) Heterozygous Reported
6 TO7 21 F 2 10 USH2A Del exon 23 > 32 p? Homozygous Reported YES
7 TO8 54 M 6 30 USH2A Del exon 31 > 35 p? Heterozygous Novel Not done
USH2A c.14977_14978del (p. Phe4993Profs*7) Heterozygous Reported
8 TO9 48 M 6 8 USH2A Del exon23 > 32 p? Heterozygous Reported YES
USH2A c.2299del (p.Glu767Serfs*21) Heterozygous Reported
8 TO10 46 F 7 18 USH2A Del exon 23 > 32 p? Heterozygous Reported YES
USH2A c.2299del (p.Glu767Serfs*21) Heterozygous Reported
9 TO11 31 M 3 mo 19 MYO7A c.849 G > A (p.Met283Ile) Homozygous Novel YES
10 TO12 16 M 3 16 USH2A c.1055C > T (p.Thr352Ile) Heterozygous Reported YES
USH2A c.10450C > T (p.Arg3484*) Heterozygous Reported
10 TO13 20 F 3 18 USH2A c.1055C > T (p.Thr352Ile) Heterozygous Reported YES
USH2A c.10450C > T (p.Arg3484*) Heterozygous Reported
11 TO14 45 M 7 20 USH2A c.269A > G (p.Tyr90Cys) Heterozygous Reported YES
USH2A c.14977_14987del (p.Phe4993Profs*7) Heterozygous Reported
12 TO15 33 F 7 7 USH2A c.908G > A (p.Arg303His) Heterozygous Reported YES
USH2A c.14803C > T (p.Arg4935*) Heterozygous Reported
13 TO16 12 M Cong 1 MYO7A c.5617C > T (p.Arg1873Trp) Heterozygous Reported YES
MYO7A c.1935 + 4A > T p? Heterozygous Novel
13 TO17 23 M 18mo 4 MYO7A c.5617C > T (p.Arg1873Trp) Heterozygous Reported YES
MYO7A c.1935 + 4A > T p? Heterozygous Novel
14 TO18 30 M 6 16 USH2A c.1000C > T (p.Arg334Trp) Heterozygous Reported YES
USH2A c.15208G > T (p.Glu5070*) Heterozygous Novel
15 TO19 20 M 11mo 17 USH2A c.5933_5940del p.Pro1978Glnfs*5 Homozygous Reported YES
USH2A c.5950_5960dup p.Tyr1987* Homozygous Novel YES
16 TO20 28 F 4 15 USH2A c.908G > A (p.Arg303His) Homozygous Reported YES
17 TO21 53 M 5 38 ADGRV1 c.3334G > T p.Glu1112* Homozygous Novel Not done
Table 1. Patients’ phenotypes and mutations identified in Usher genes. HL = hearing loss; VI = visual 
impairment; *Age at counselling and genetic testing; M = male; F = female; yrs = years; mo = months; 
cong = congenital.
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the most frequent clinical diagnosis, accounting for 81% of the patients, while USH1 was diagnosed in 19%. None 
of the patients were affected by USH3.
24 likely pathogenic variants - 17 previously reported and 7 novel - were identified in three genes (USH2A, 
MYO7A, ADGRV1). Five mutations were detected in MYO7A, two of which were novel; 18 mutations were iden-
tified in USH2A (4 of which novel) and one novel homozygous mutation was identified in ADGRV1. Additional 
variants with uncertain pathogenic significance in USH2A, MYO7A, ADGRV1, CDH23 genes were further identi-
fied in 9 patients. In these patients, the additional variants were not considered to be the main causative mutations 
because two other causative variants were present (reported or novel but with a strong impact at the protein level). 
We cannot exclude a modifier role for these uncertain variants.
Genetic testing result was in accordance with previous clinical diagnosis or clinical suspicion for all patients. 
All subjects with USH1 or suspected USH1 displayed biallelic MYO7A mutations and all subjects with USH2 
presented at least two USH2A or two ADGRV1 mutations. Such results are in line with previous studies that 
report MYO7A and USH2A gene mutations being among the most frequent causes of USH1 and USH217. The 
frameshift mutation c.2299delG (p.Glu767Serfs*21) in the USH2A gene was the most frequent in our cohort, 
since it was detected in 6 patients from four unrelated families. This mutation is quite frequent (0.16 to 0.44) in 
several cohorts of patients18–21. According to current literature, this is the most common mutation in European 
patients, accounting for approximately 30% of all European cases of USH2A22. The high frequency of such muta-
tion has been reported in several different populations and was proven to be the result of an ancestral mutation 
that has then spread throughout Europe and other continents due to migratory movements23.
Segregation analysis revealed three patients (TO15, TO18 and TO19) with a USH2A allele carrying more than 
one mutation. This finding underlines the importance of performing segregation analysis on patients suffering 
from recessive disorders to identify the exact genotype. Although such thoroughness adds up to the costs, it is 
essential for genetic counselling and reliable family risk evaluation.
Family Patient Age* Sex Onset HL (yrs) Onset VI (yrs) Gene Mutation Protein Reported Segregation
6 TO7 21 F 2 10 MYO7A c.6424G > A p.Asp2142Asn Heterozygous Reported YES
ADGRV1 c.6133G > A p.Gly2045Arg Heterozygous Novel
CDH23 c.4858G > A p.Val1620Met Heterozygous Reported
7 TO8 54 M 6 30 ADGRV1 c.11272C > A (p.Gln3758Lys) Heterozygous Novel Not done
9 TO11 31 M 3 mo 19 USH2A c.1407G > A (p.Gly4692Arg) Heterozygous Reported YES
11 TO14 45 M 7 20 CDH23 c.4858G > A (p.Val1620Met) Heterozygous Reported YES
12 TO15 33 F 7 7 USH2A c.688G > A (p.Val230Met) Heterozygous Reported YES
13 TO16 12 M Cong 1 ADGRV1 c.6133G > A (p.Gly2045Arg) Heterozygous Novel YES
13 TO17 23 M 18mo 4 ADGRV1 c.6133G > A (p.Gly2045Arg) Heterozygous Novel YES
14 TO18 30 M 6 16 USH2A c.5858C > G (p.Ala1953Gly) Heterozygous Reported YES
USH2A c.14527 A > G (p.Arg4843Gly) Heterozygous Novel
15 TO19 20 M 11mo 17 ADGRV1 c.11974G > A (p.Asp3992 Asn) Heterozygous Novel YES
Table 2. Additional variants in Usher genes. HL = hearing loss; VI = visual impairment; *Age at counselling 
and genetic testing; M = male; F = female; yrs = years; mo = months; cong = congenital
Change in dbSNP Prediction algorithms
Nucleotide Protein ID MAF (%) phyloP SIFT PolyPhen2
Mutation 
Taster
Align 
GVGD
USH2A
c.563A > G p.Tyr188Cy NA 0 Moderately conserved nucleotide Deleterious
Probably 
damaging
Disease 
causing C0
del exon 31- > 35 p.? — — — — —
c.15208G > T p.Glu5070* NA 0 — — — — —
c.5950_5960dup p.Tyr1987* NA 0 — — — — —
MYO7A — — — — —
c.849 G > A p.Met283Ile NA 0 Moderately conserved nucleotide Tolerated Benign
Disease 
causing C0
c.1935 + 4 A > T p.? NA 0 — — — — —
ADGRV1
c.3334 G > T p.Glu1112* NA 0 — — — — —
Table 3. New mutations: frequency in control population and pathogenicity prediction MAF = minor allele 
frequency; SIFT = sorting intolerant from tolerant; PolyPhen2 = polymorphism phenotyping; NA = not 
applicable.
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Patient Age* Sex BCVA Anatomic changes GVF CME Hearing changes Vestibular function Other
TO1 47 F RE: 0.05 LE: 0.04
Bilateral cataract, RP sine 
pigmento,
Residual bilateral 
10° Absent
Bilateral progressive 
pantonal neurosensory 
hearing loss
Subjective equilibrium 
impairment in the 5th 
decade
TO2 35 M RE: 0.2 LE: 0.25 Bilateral cataract N/A
Macular hole 
in RE
Bilateral progressive 
neurosensory hearing 
loss
No subjective equilibrium 
impairment
TO3 29 M RE: 0.2 LE: 0.25
Bilateral cataract, bilateral 
pigment deposits
Residual bilateral 
10° N/A
Bilateral non progressive 
post lingual hearing loss
No subjective equilibrium 
impairment
TO4 17 M RE: 0.4 LE: 0.6 Bilateral pigment deposits
Residual bilateral 
10° N/A
Bilateral neurosensory 
hearing loss
No subjective equilibrium 
impairment Vestibular test 
normal
Two episodes of 
absence seizure
TO5 58 M RE: 0.8 LE: 0.6
Bilateral cataract, bilateral 
pigment deposits
Residual bilateral 
20° N/A
Bilateral neurosensory 
median and high 
frequencies hearing loss
No subjective equilibrium 
impairment
TO6 32 M RE: 0.3 LE: 0.3
Bilateral cataract, bilateral 
pigment deposits
RE: Residual isle in 
temporal-superior, 
LE: reduction of 
sensibility and nasal 
deficit
N/A Bilateral congenital hearing loss
Delayed walking.
Vestibular test abnormal
TO7 21 F RE: 0.4 LE: 0.2
Bilateral pigment deposits, 
vitreo-macular traction
Residual 
bilateral < 10°
Present 
bilateral
Bilateral congenital 
moderate/profound 
hearing loss
Delayed walking 
Vestibular test abnormal
TO8 54 M RE: 0.8 LE: 0.4
Bilateral cataract, bilateral 
pigment deposits, 
peripapillary atrophy, 
macular pucker,
RE: Residual central 
6–10° LE: Residual 
central 10–15°
N/A
Bilateral pan-tonal 
non progressive severe 
neurosensory hearing 
loss
Vestibular test abnormal Migraine episodes
TO9 48 M RE: 0.5 LE: 0.7
Bilateral cataract, bilateral 
pigment deposits, 
peripapillary atrophy.
Residual bilateral 
10° N/A
Bilateral pan tonal severe 
neurosensory hearing 
loss
Vestibular test abnormal
TO10 46 F N/A N/A N/A N/A Bilateral moderate hearing loss
Subjective equilibrium 
impairment
TO11 31 M RE: 0.95 LE: 0.95 Bilateral pigment deposits
Residual bilateral 
20° Present
Bilateral congenital 
progressive severe 
hearing loss, bilateral 
cochlear implant
No subjective equilibrium 
impairment. Walked at 13 
months
TO12 16 M RE: 1 LE: 1
Bilateral pigment deposits 
and atrophic areas N/A
Present 
bilateral
Bilateral congenital 
hearing loss, hearing aids
No subjective equilibrium 
impairment
TO13 20 F RE: 0.9 LE: 0.5
Bilateral pigment deposits, 
optic nerve head drusen
Residual bilateral 
20° Present
Bilateral mild hearing 
loss
No subjective equilibrium 
impairment
GJB2 wild-type 
Headache, recurrent 
sinusitis and 
bronchitis
TO14 45 M RE: 1 LE: 1
Bilateral cataract, bilateral 
pigment deposits
Residual bilateral 
10° Absent
Bilateral mild progressive 
neurosensory hearing 
loss
Subjective equilibrium 
impairment Neonatal jaundice
TO15 33 F N/A Bilateral pigment deposits Residual bilateral 20° Absent
Bilateral mild 
high frequencies 
neurosensory hearing 
loss
No subjective equilibrium 
impairment. Vestibular 
test normal
Migraine. CPT2 gene 
mutations associated 
myopathy
TO16 12 M RE: 0.7 LE: 0.5
Abnormal macular reflex, 
pale optic disk, no pigment 
deposit
N/A Present LE
Bilateral congenital 
hearing loss, cochlear 
implant
Delayed walking (18 
months)
Pervasive 
development disorder
TO17 23 M RE: 1 LE: 0.15
Bilateral cataract, bilateral 
pigment deposits, 
peripheral retinal 
teleangectasia, vitreous 
hemorrhage in LE, optic 
disk drusen
Residual bilateral 
10° Present LE
Bilateral congenital 
severe hearing loss, 
cochlear implant
Delayed walking (24 
months) Vestibular test 
abnormal
Scleral buckling and 
vitrectomy in LE for 
retinal detachment. 
GJB2 wild-type
TO18 30 M RE: 0.55 LE: 0.45 Bilateral pigment deposits
Reduced sensitivity 
with paracentral 
scotomatous areas
Present 
bilateral
Bilateral progressive 
neurosensory hearing 
loss,hearing aids
No subjective equilibrium 
impairment
Liver angioma GJB2 
wild-type
TO19 20 M RE: 0.9 LE: 0.8 Bilateral pigment deposits
Residual bilateral 
10° N/A
Bilateral progressive 
mild post lingual 
neurosensory hearing 
loss
No subjective equilibrium 
impairment Dorsal scoliosis
TO20 28 F RE: 0.5 LE: 0.5
Bilateral cataract, bilateral 
pigment deposits
Residual bilateral 
10° Absent
Bilateral progressive 
mild post lingual 
neurosensory hearing 
loss
Normal
Several episodes of 
loss of consciousness, 
abnormal EEG
TO21 53 M RE: 0.5 LE: 0.6
Bilateral cataract. bilateral 
pigment deposits
Residual bilateral 
10° N/A
Bilateral progressive 
severe post lingual 
neurosensory hearing 
loss
No subjective equilibrium 
impairment
Table 4. Clinical characteristics. RE, right eye; LE, left eye; BCVA, best corrected visual acuity; GVF, Goldmann 
Visual Field; CME, cystoid macular edema; N/A, not available; EEG; electroencephalogram.
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All subjects with USH1 and biallelic MYO7A mutations were diagnosed with deafness and vestibular func-
tion impairment within their first 18 months of life. This lead to an initial clinical diagnosis of myopathy with 
neurodevelopmental delay in one patient (TO17), while the brother (TO16) was diagnosed with a pervasive 
developmental disorder. For all patients, deafness was initially attributed to a possible prenatal or postnatal infec-
tion. Three patients were tested in early childhood for GJB2 gene mutations, since this gene is deemed to be the 
leading cause for hereditary deafness within the European population24. At the time of diagnosis, the absence of 
pathogenic variants in GJB2 gene had, in fact, misled the physician in reinforcing the hypothesis of an infective 
aetiology of deafness. The parents of two of these patients, having been reassured about a low risk of recurrence, 
had a second affected child. This further stresses the fundamental importance of providing an exact diagnosis to 
children affected by deafness. Such diagnosis can be accomplished by offering targeted NGS for syndromic and 
non-syndromic deafness-related genes whenever prenatal or postnatal infective aetiology is not documented.
Visual symptoms have also proven to occur at an early age, ranging from 1 to 6 years, hence well before the age 
of 10, as generally observed in USH1 subjects25. Only patient TO11 had a late onset of visual symptoms, which 
went unnoticed until he was 19. This patient has a novel homozygous missense mutation in MYO7A gene that 
might have a milder effect on retinal function.
A recent study on the Italian population confirms that hearing and visual impairment generally occur at an 
earlier age in patients carrying MYO7A mutations compared to those carrying USH2A mutations. The mean age 
for hearing loss and visual symptoms is generally between 5 ± 1 months and 16 ± 3 years respectively26.
Patients with USH2 carrying USH2A or ADGRV1 mutations were diagnosed deaf and displayed visual symp-
toms at an older age compared to subjects with MYO7A mutations. Deafness usually occurred between 11 months 
and 14 years (mean age 5 years) within the reported range 8 months – 31 years27, whereas visual impairment 
generally onsets later, among 10 to 38 year old, (mean 15 ± 8.4 years) again within the reported age range 8–76 
(average age 35.5)27. Two homozygous c.5933_5940del and 5950_5960dup mutations in USH2A were detected in 
patient TO19, whose deafness onset was recorded when he was 11 months old and whose visual symptoms were 
noticed only later when he was 17 years old.
The age at which the patients with USH2 in our cohort lamented symptoms was generally earlier than what a 
recent study on Italian patients with USH17 reports. The study comprises 36 patients (three USH1 and 33 USH2) 
and reports the average age of visual symptoms onset to be 17.5 ± 8.8 years. OCT revealed macular oedema in 
29% of the patients in our study, a comparable percentage of cystoid macular lesions (from 28 to 49% in different 
studies) were similarly reported in studies on patients with RP28–30.
In conclusion, patients with USH exhibited clinical severity, which appears to be related to the mutated 
gene and to the specific type of mutation. Homozygosity for deletion from exon 23 to 32 and homozygosity for 
c.5933_5940del and c.5950_5960dup in USH2A were associated with a severe phenotype. It is known that muta-
tions in USH2A can lead either to USH2 or to non-syndromic RP. Mutations carried by USH2 patients, tend to 
be more severe than those found in non-syndromic RP patients31,32. Therefore, there is evidence that, even within 
the USH2 phenotype, there ought be a severity gradient depending on the specific mutation33,34. We also observed 
a MYO7A biallelic mutation that was generating a phenotype with vestibular dysfunction, though it entailing 
milder hearing and visual symptoms. The role of additional heterozygous mutations in other related Usher genes 
remains to be further investigated.
These results, thus, provide useful data not only for tailored genetic counselling but they also provide addi-
tional clues for early clinical diagnosis of patients with Usher syndrome.
Nevertheless, this study present some limits. The heterogeneity of the clinical information available, in fact, 
did not allow for statistical analysis.
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